Sol-Gel Technologies SLGL 深 沪
等待开盘 12-18 09:30:00 美东时间
41.15
-0.975
-2.31%
华盛通- 最 高43.00
- 今 开43.00
- 成交量 1.36万股
- 最 低 39.26
- 昨 收 42.125
- 总市值 1.15亿
- 52周最高 52.26
- 市盈率 静 --
- 换手率 0.49%
- 52周最低 4.018
- 委 比 0.50%
- 总股本 278.58万
- 历史最高 210.00
- 量 比 1.20
- 振 幅 8.88%
- 历史最低 3.34
- 每 手 1
- 风险率 12.84%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Is Small Cap Sol-Gel Tech Stock Falling Today?
Sol-Gel Technologies ends development of SGT-210 in Darier disease after Phase 1b data show no efficacy versus vehicle.
今天 02:47
Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease
Sol-Gel Technologies Ltd. announced that its Phase 1b study of SGT-210 for Darier disease showed no significant difference between the treatment and placebo, leading to the decision to halt further development for this indication. The company plans to explore feasibility studies in other areas with unmet medical needs. Sol-Gel continues to prioritize its Phase 3 trial of SGT-610 for Gorlin syndrome, aiming to prevent basal cell carcinoma in patie...
12-17 12:00
Sol-Gel Technologies Q3 EPS $(2.13) Misses $(2.09) Estimate, Sales $400.000K Beat $300.000K Estimate
Sol-Gel Technologies (NASDAQ:SLGL) reported quarterly losses of $(2.13) per share which missed the analyst consensus estimate of $(2.09) by 1.91 percent. This is a 1538.46 percent decrease over losses of $(0.13) per
11-20 20:34
Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Sol-Gel Technologies announced its Q3 2025 financial results and updates, highlighting progress on its lead drug candidate SGT-610 for Gorlin syndrome with plans to pursue an additional indication for high-frequency basal cell carcinoma (BCC), potentially doubling its commercial potential. The company also secured Health Canada approval for EPSOLAY and signed a new agreement with Viatris for its distribution in Australia and New Zealand. Financia...
11-20 12:30
美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
10-28 10:08
HC Wainwright & Co. Maintains Buy on Sol-Gel Technologies, Raises Price Target to $50
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Sol-Gel Technologies (NASDAQ:SLGL) with a Buy and raises the price target from $6 to $50.
10-27 19:04
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers ModivCare (NASDAQ:MODV) stock rose 116.1% to $1.21 during Friday's reg...
08-23 01:06
Sol-Gel Technologies Q2 EPS $4.17 Beats $(0.07) Estimate, Sales $17.261M Beat $2.900M Estimate
Sol-Gel Technologies (NASDAQ:SLGL) reported quarterly earnings of $4.17 per share which beat the analyst consensus estimate of $(0.07) by 6057.14 percent. This is a 495.71 percent increase over earnings of $0.70 per
08-15 19:16
Sol-Gel Technologies Q1 EPS $(3.20) Vs. (2.30) Prior Year, Sales $1.03M Miss $1.20M Estimate
Sol-Gel Technologies (NASDAQ:SLGL) reported quarterly losses of $(3.20) per share. This is a 39.13 percent decrease over losses of $(2.30) per share from the same period last year. The company reported quarterly sales of
05-23 19:25
Sol-Gel Technologies Regains Nasdaq Compliance
Sol-Gel Technologies ( ($SLGL) ) has provided an announcement. Sol-Gel Technolo...
05-23 04:28
